|EJMCR. 2017; 1(3): 135-139
Exceptional response after metronomic chemotherapy and palliative radiotherapy in castration-resistant prostate cancer: A case report
Alessio Giuseppe Morganti, Gabriella Macchia, Rezarta Frakulli, Andrea Milanoi, Francesco Massari, Maria Ntreta, Giambattista Siepe, Alessandra Arcelli, Silvia Cammelli, Giuseppe Zanirato Rambaldi, Michelangelo Fiorentino, Francesco Deodato.
|Cited by 0 Articles|
Castration-resistant prostate cancer (CRPC) has a dismal prognosis. Despite treatment, median survival of these patients is around 12-22 months.
In this report, we present the case of a 71-year-old man, with CRPC and painful bone metastases treated with an association of middle-half-body radiotherapy, androgen deprivation therapy (ADT) and cyclophosphamide-based metronomic chemotherapy. Five years after palliative radiotherapy the patient is still receiving metronomic chemotherapy and ADT. He is totally asymptomatic, with undetectable PSA values and negative 18F-Choline-PET/CT. The only side-effect was the development of non-insulin-dependent diabetes.
This treatment for its tolerability and feasibility, it could be particularly useful in older patients with CRPC. Furthermore, considering the low costs, it could be an important therapeutic option for patients living in low-resourced countries.
Key words: Metronomic chemotherapy, radiotherapy, prostate neoplasms, CRPC, case report